If approved, levacetylleucine could become the first therapy on the market for ataxia-telangiectasia.

CARVYKTI ® is the first and only BCMA-targeted CAR-T cell therapy approved for the treatment of patients with multiple myeloma who have had at least one prior line of therapy. Globally, CARVYKTI ® is ...

Phase 3 trial results show levacetylleucine improves SARA scores in patients with the rare disorder ataxia-telangiectasia.

A brain cap and smart algorithms may one day help paralyzed patients turn thought into movement—no surgery required.

A breakthrough method from the 1990s is now being transformed into an AI-powered tool to help doctors diagnose cerebral palsy ...

Flexibility test at 60, guided by a certified trainer, using 3 seated movements to assess hips, spine, and hamstrings.

The DWP has issued a full list of 533 conditions which could qualify you for a £187 a week payment. Personal Independence ...

A new wave of research is showing what the old gym myths about stretching got wrong—and what you really need to do to reap its benefits.

PIP is broken down into two parts with daily living starting at £73.90 for the lower rate, rising to £110.40 for higher ...

A rare Homo habilis skeleton from Kenya reveals how early humans moved, climbed, and adapted more than two million years ago.